Ionis Pharmaceuticals, Inc. 的合作伙伴葛兰素史克宣布，其研究性疗法Bepirovirsen在慢性乙型肝炎的临床试验中取得了前所未有的功能性治愈率，这一突破性成果有望彻底重塑该疾病的治疗格局。
该药物展现出的潜力标志着慢性乙肝治疗领域的一个重大飞跃。功能性治愈，即患者体内检测不到乙肝病毒表面抗原且病毒DNA水平极低，长期以来一直是该领域追求的终极目标。Bepirovirsen所达到的治愈率数据，为全球数百万慢性乙肝患者带来了新的希望，预示着治疗范式可能发生根本性转变。
这一积极进展不仅对患者意义重大，也进一步巩固了Ionis与葛兰素史克在创新疗法开发方面的合作成果。Bepirovirsen的成功验证了其独特的作用机制，为最终攻克慢性乙型肝炎这一全球性健康挑战开辟了新的道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.